Wanbury Limited

NSE WANBURY.NS

Wanbury Limited Revenue for the year ending March 31, 2024: USD 69.01 M

Wanbury Limited Revenue is USD 69.01 M for the year ending March 31, 2024, a 13.53% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Wanbury Limited Revenue for the year ending March 31, 2023 was USD 60.79 M, a -9.00% change year over year.
Wanbury Limited Revenue for the year ending March 31, 2022 was USD 66.80 M, a 26.36% change year over year.
Wanbury Limited Revenue for the year ending March 31, 2021 was USD 52.87 M, a 9.87% change year over year.
Wanbury Limited Revenue for the year ending March 31, 2020 was USD 48.12 M, a -13.58% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NSE: WANBURY.NS

Wanbury Limited

CEO	Mr. Pradeep Patni
IPO Date	Jan. 29, 2007
Location	India
Headquarters	BSEL Tech Park, B-Wing
Employees	1,491
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Key trends

Past 5 years